The output is determined using a machine-learning algorithm that has been trained and tested on thousands of benign and malignant lesions. Benign lesions have been trained to provide a “Lower Risk” output whereas malignant lesions, such as melanoma, SCC, and BCC have been trained to provide a “Higher Risk” output.
This output provides you with objective information designed to augment your clinical decision making and can be included in your clinical notes.
You can find the most current information and literature on DermaSensor™
device performance at www.DermaSensor.com.